Treatment of children with acute lymphoblastic leukemia (ALL) in the Czech Republic was unified during the second half of the 1980s through the gradual introduction of protocol ALL-BFM 83 at the individual departments of pediatrics of regional and/or teaching hospitals (eight centers overall, five of which are affiliated to a medical school). During that period, the Working Group for Pediatric Hematology in the Czech Republic (CPH) was established, and recommendations for uniform diagnostic approaches for pediatric ALL were developed. ALL-BFM 90 therapy was used by all eight centers over a period spanning from 1990 to 1996 and data were collected in a central site. All patients enrolled into the study had immunophenotyping and cytogenetics performed at selected centers with better equipment and experience, whereas screening for BCR/ABL and MLL/AF4 by PCR was carried out at a single national reference laboratory. Patients were stratified into three risk groups according to the original criteria of ALL-BFM 90; however, they were not randomized using the corresponding standard therapeutic arms of the study.
1,2 The use of high-dose methotrexate (5 g/m 2 ) was introduced at the individual centers gradually during the study, and prophylactic cranial radiotherapy at 12 Gy was applied in children with medium-and high-risk disease. Study ALL-BFM 95 was conducted from 1996 to 2002, with a central review of morphology at initial diagnosis and at relapse, screening of all patients for BCR/ABL, MLL/AF4 and TEL/AML1 gene rearrangements by PCR at one reference molecular biology laboratory and immunophenotyping of all cases at one central reference flow cytometry laboratory. Risk-group stratification of patients was performed as stipulated by the original German-Austrian-Swiss study. 3 In this trial too, treatment was given according to the corresponding standard arms, and prophylactic cranial radiotherapy at 12 Gy was reserved only for children with T-ALL or high-risk disease. Medium-risk patients were randomized within the I-BFM-SG trial to receive either conventional maintenance treatment with daily 6-mercaptopurine and weekly methotrexate, or pulses of dexamethasone and vincristine, in addition to conventional oral therapy. 4 Infants younger than 1 year were managed according to protocol POG 9407 (n ¼ 5) or Interfant 99 (n ¼ 13). Cranial radiotherapy was omitted for all infants o1 year of age. Eventfree survival (EFS) was defined as the time from diagnosis until induction failure, relapse, death from any cause or second cancer. Patients surviving event free were censored at date of last follow-up. Cases that did not achieve complete remission were considered failures at time zero. EFS and overall survival (OS) were estimated by Kaplan-Meier life-table analysis, and the log-rank test was used to assess differences in survival. Univariate analysis was used to identify prognostic factors for EFS and OS, whereby a P-value o0.05 was considered significant. For patients who attained complete remission, the cumulative incidence functions of isolated or any central nervous system (CNS) relapse, as well as the cumulative incidence functions of developing a therapy-related second malignancy, were drawn by the method of Kalbfleisch and Prentice.
The results of treatment are given in Table 1 . In all, 350 and 380 children up to 18 years of age were enrolled into ALL-BFM 90 and ALL-BFM 95, respectively. EFS was similar between the two trials (ALL-BFM 90: 70.5 ± 2.4% vs ALL-BFM 95: 72.1±2.3%; P ¼ 0.56), with a trend toward a significantly better survival in ALL-BFM 95 (P ¼ 0.18) (Figures 1 and 2) . The cumulative risk of death in remission was lower in ALL-BFM 95 (3.9 ± 1.0%) compared with ALL-BFM 90 (5.2 ± 1.2%). Figure 1 Event-free survival (EFS), survival and cumulative incidence of any central nervous system (CNS) relapse in the ALL-BFM 90 study.
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The cumulative risk of isolated CNS and any CNS relapse was 0 and 1.8 ± 0.8% at 15 years in BFM 90 vs 1.2 ± 0.6 and 2.5 ± 0.9% at 10 years in BFM 95 (Figures 1 and 2 ). Prophylactic cranial irradiation was applied in 184 (52.6%) of 350 children in ALL-BFM 90 and in 71 (18.7%) of 380 patients in the ALL-BFM 95 study. The cumulative hazard of second malignancy was 1.9 ± 0.8% at 15 years in ALL-BFM 90, and 0.6 ± 0.4% at 10 years of diagnosis in ALL-BFM 95. Two patients in ALL-BFM 90 and seven children in ALL-BFM 95 received an allogeneic stem cell transplantation in first remission. Tables 2 and 3 show treatment results according to prognostic factors. In both trials, the National Cancer Institute risk group, age and initial leukocyte count were shown to be significant for prognosis on univariate analysis. There was a low incidence of CNS relapse, despite the marked reduction in the use of cranial radiotherapy between the 95 and 90 protocols. No patients from 
